WORTHING, UNITED KINGDOM--(Marketwired - May 9, 2016) - Allergy Therapeutics (AIM: AGY)


9 May 2016

Allergy Therapeutics plc
("Allergy Therapeutics" or the "Company")

Allergy Therapeutics announces positive top-line results from the PQBirch204 Phase II study for birch-induced seasonal allergic rhinitis

  • Primary endpoint met
  • Statistically significant dose-response relationship (p < 0.01)
  • All dosing regimens were safe and well tolerated
  • Adherence was greater than 90%

Allergy Therapeutics, (AIM: AGY), the fully integrated specialty pharmaceutical company specialising in allergy vaccines, today announces positive top-line results from the Company's PQBirch204 Phase II study, a multi-centre, double-blind, placebo-controlled study designed to explore the safety and response of different cumulative doses of Birch Modified Allergen Tyrosine adsorbed and MPL® (POLLINEX® Quattro Birch) for birch pollen induced seasonal allergic rhinitis.

The study randomised 371 patients into six cumulative dosing regimens plus a placebo, evaluating the change in Total Symptom Score (TSS) following a conjunctival provocation test (CPT) with the objective to achieve a dose recommended for Phase III development.

Results summary of the PQBirch 204 Phase II study programme

  • The primary endpoint, to demonstrate a statistically significant (p < 0.01) dose-response for the 5000 standardised units (SU) to 27300 SU, was met. This enables prediction of the dose to enter Phase III development
  • The study demonstrated a statistically significant (p < 0.01) dose-response for the 5000 standardised units (SU) to 27300SU dose range studied
  • The dose-response closely followed and extended the findings of the previous dose-response study (PQBirch203), which studied doses from 600SU to 13600SU
  • PQBirch continues to be well-tolerated and no safety concerns were reported in any treatment arm. There was no significant relationship between any adverse drug reaction exhibited and the respective dosage of allergoid
  • Overall adherence to the dosing regimens was approximately 94% with no relevant differences between treatment arms.

Click on, or paste the following link into your web browser, to view the associated PDF document.


This information is provided by RNS

The company news service from the London Stock Exchange

Contact Information:

For further information, please contact:

Allergy Therapeutics
+44 (0) 1903 845 820
Manuel Llobet
Chief Executive Officer

Panmure Gordon
+44 (0) 20 7886 2500
Freddy Crossley / Peter Steel / Duncan Monteith, Corporate Finance
Tom Salvesen, Corporate Broking

Consilium Strategic Communications
+44 20 3709 5700
Mary-Jane Elliott / Ivar Milligan / Matthew Neal / Laura Thornton